Table 5.

Risk for squamous-cell carcinoma (SCC) of the buccal cavity and skin, according to chronic GVHD and duration of therapy

	SCC buccal cavity				SCC skin
Risk factors	Case patients, no.	Control patients, no.	RR*	95% CI	Case patients, no.	Control patients, no.	RR	95% CI
Model 1: chronic GVHD
No	5	24	1.00	Reference	3	29	1.00	Reference
Yes	19	42	2.35	0.70-7.93	16	22	14.46	1.84-113.3
Unknown	0	1	-	-	-	-	-	-
Model 2: total duration of prophylaxis, acute and chronic GVHD therapy
None, less than 12 mo	7	34	1.00	Reference	7	32	1.00	Reference
12-23 mo	4	18	1.14	0.28-4.67	3	12	2.00	0.38-10.36
24 mo or more	13	14	5.65	1.53-20.79	9	7	12.00	2.02-71.38
Unknown	0	1	-	-	-	-	-	-
Model 3: duration of chronic GVHD therapy
None, less than 12 mo	9	40	1.00	Reference	8	41	1.00	Reference
12-23 mo	4	17	0.99	0.25-3.93	3	6	2.32	0.42-12.91
24 mo or more	11	9	6.76	1.71-26.69	8	4	20.30	2.41-171.0
Unknown	0	1	-	-	-	-	-	-
Model 4: chronic GVHD drug therapy
None, other, no CSP, no AZA	9	41	1.00	Reference	7	38	1.00	Reference
CSP, no AZA	3	13	0.78	0.17-3.51	2	8	1.23	0.13-11.78
Any AZA	11	11	5.47	1.41-21.16	10	5	20.84	2.57-169.1
Unknown CSP/AZA	1	2	-	-	-	-	-	-

For SCC buccal cavity, there were 24 case patients and 67 control patients; for SCC skin, there were 19 case patients and 51 control patients.

^*Adjustment for smoking/alcohol consumption (at time of transplantation) in the buccal cavity model led to similar risk estimates